ENDACEA

Biopharmaceutical Pipeline – Highly Innovative Products Designed to Save Lives

The biopharmaceutical pipeline of ENDACEA contains innovative and significant treatments that can potentially address a number of health conditions, including cancer. These products are currently in the preclinical stage of development. Get in touch for more information.

Indication: COVID-19 Acute Lung Injury

ENDACEA is collaborating with TFF Pharmaceuticals, a publicly-traded company, to develop L-97-1 as an inhalational treatment for COVID-19 acute lung injury.

  • Compound: L-97-1
  • Indication: COVID-19 Acute Lung Injury
  • Mechanism of Action: A1 AR antagonist
  • Formulation: Inhalational
  • Phase of Development: Preclinical

Indication: Sepsis and Renal Failure

ENDACEA is developing its lead compound A1 adenosine receptor antagonist, L-97-1, as an intravenous treatment for sepsis and acute renal failure.

  • Compound: L-97-1
  • Indication: Sepsis and Renal Failure
  • Mechanism of Action: A1 AR antagonist
  • Formulation: Intravenous
  • Phase of Development: Preclinical

Indication: Cancer

ENDACEA is developing a mutant plasmid cDNA for the A1 adenosine receptor for a cancer treatment. When this treatment was administered as an intratumor injection in mice with prostate cancer, the tumor volume was reduced by 84 percent.

  • Compound: Mutant plasmid cDNA
  • Indication: Cancer
  • Mechanism of Action: Protein Correction
  • Formulation: Intratumor
  • Phase of Development: Preclinical

About L-97-1

ENDACEA’s lead compound A1 adenosine receptor (AR) antagonist, L-97-1, is a “best in class” A1 AR antagonist. This compound has a high affinity and selectivity for the human A1 AR, is a water-soluble small molecule, and has high oral bioavailability. In addition, this compound is an analog of an approved off-patent currently-marketed anti-asthma drug that is an A1 AR antagonist. Based on the completed IND-enabling GLP toxicology studies, ENDACEA expects that L-97-1 will be a safe drug with a high therapeutic index.

Following high dose oral administration, L-97-1 produced no seizure activity in a pro-convulsant animal model. It fits Lipinski’s rule of 5 for a successful orally active drug and is a Biopharmaceutics Classification System (BCS) Class 1 compound. Further, L-97-1 has a long shelf-life, can be stored at room temperature, and has a validated chemistry synthesis route with an expected low cost of goods at maturity.